Technology
Health
Pharmaceutical

Gritstone Oncology

$10.48
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.50 (5.01%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell GRTS and other stocks, options, ETFs, and crypto commission-free!

About

Gritstone Oncology, Inc. clinical-stage biotechnology company, which engages in developing the next generation of cancer immunotherapies to fight multiple cancer types. The company was founded in August 2015 by Andrew Allen, Timothy Chan, Mark Cobbold, Graham Lord, Naiyer Rizvi and Jean-Charles Soria and is headquartered in Emeryville, CA.

Employees
113
Headquarters
Emeryville, California
Founded
2015
Market Cap
304.18M
Price-Earnings Ratio
Dividend Yield
Average Volume
190.10K
High Today
$10.61
Low Today
$10.07
Open Price
$10.10
Volume
92.01K
52 Week High
$32.90
52 Week Low
$9.57

Collections

Technology
Health
Pharmaceutical
Cancer Prevention
Medical
Biotechnology
2018 IPO
US

News

Yahoo FinanceMay 13

Gritstone Oncology Reports First Quarter 2019 Financial Results and Recent Highlights

EMERYVILLE, Calif., May 13, 2019 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (GRTS), a clinical-stage biotechnology company developing the next generation of cancer immunotherapies to fight multiple cancer types, today reported recent business highlights and financial results for the first quarter ended March 31, 2019. “In a short period, we have made remarkable progress advancing our development programs, as well as expanding and enhancing our best-in-class artificial intelligence platform, Gritstone EDG...

42
Yahoo FinanceMay 9

Here’s What Hedge Funds Think About Gritstone Oncology, Inc.

You probably know from experience that there is not as much information on small-cap companies as there is on large companies. Of course, this makes it really hard and difficult for individual investors to make proper and accurate analysis of certain small-cap companies. However, well-known and successful hedge fund managers like Jeff Ubben, George Soros and Seth Klarman hold the necessary resources and abilities to conduct an extensive stock analysis on small-cap stocks, which enable them to make millions ...

50
Simply Wall StMay 9

Could The Gritstone Oncology, Inc. (NASDAQ:GRTS) Ownership Structure Tell Us Something Useful?

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! The big shareholder groups in Gritstone Oncology, Inc. (NASDAQ:GRTS) have power over the company. Institutions often own shares in more established companies, while it’s not unusual to see insiders own a fair bit of smaller companies. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, ‘Don’t tell me what you think, tell me w...

14

Earnings

-$7.60
-$5.26
-$2.93
-$0.59
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.65 per share
Actual
-$0.62 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.